Explanipedia

Ravulizumab as an alternative for gemcitabine related trombotic microangiopathy: A case report Open

Cristina Riaza Ortiz, Marta Calvo Arévalo, Marta Álvarez Nadal, Antonio Casado da Rocha, Ana Sánchez‐Fructuoso , et al. · 2025

Thrombotic microangiopathy (TMA) is characterized by endotelial damage, microangiopathic hemolytic anemia, thrombocytopenia and organ damage, particularly renal. In Oncology, TMA can be secondary to the cancer itself or related to oncologi…

GLANCE survey: awareness and implementation of the GLOSEN recommendations for the diagnosis and treatment of lupus nephritis Open

Manuel Macía, Ana I Ávila, M. Espino Hernández, Marío de la Torre Espinosa, Xavier Fulladosa , et al. · 2025

In 2023, the Spanish Society of Nephrology's Glomerular Diseases Study Group (GLOSEN) published a consensus document containing the most pertinent information and clinical recommendations for the diagnosis, treatment, and follow-up of lupu…

Experience with new anti-CD20 monoclonal antibodies for immune-mediated glomerulopathies in a tertiary hospital Open

Jorge Iván Zamora, Marina López-Martínez, Natàlia Ramos, Sheila Bermejo, Irene Agraz , et al. · 2025

In the recent years, new humanized anti-CD20 monoclonal antibodies have been developed to optimize B-cell depletion. Our objective is to describe the experience at our center with the use of new anti-CD20 drugs in glomerular diseases. We i…

Ravulizumab como alternativa en la microangiopatía trombótica inducida por gemcitabina: reporte de un caso clínico Open

Cristina Riaza Ortiz, Marta Calvo Arévalo, Marta Álvarez Nadal, Antonio Casado, Ana Sánchez‐Fructuoso , et al. · 2025

Encuesta GLANCE: conocimiento e implementación de las recomendaciones del documento de GLOSEN para el diagnóstico y tratamiento de la nefritis lúpica Open

Manuel Macía, Gema Fernández‐Juárez, Ana I Ávila, M. Espino Hernández, Marío de la Torre Espinosa , et al. · 2025

Greener Nephrology: A Strategic Imperative for Sustainable Kidney Care Open

Clara García-Carro, Prakash Gudsoorkar · 2025

Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology Open

Núria Montero, Laia Oliveras, Alberto Martínez‐Castelao, José Luis Górriz, María José Soler , et al. · 2025

To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to p…

Does low-dose spironolactone increase cardiovascular protection in patients with chronic kidney disease? Open

Clara García-Carro, Pantelis Sarafidis · 2025

F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor–associated acute kidney injury Open

Shruti Gupta, Olivia Green‐Lingren, Sudhir Bhimaniya, Aleksandra A. Krokhmal, Heather A. Jacene , et al. · 2024

WCN24-2513 TRANSIENT ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES Open

María José Soler Romeo, Gloria Iacoboni, Sheila Bermejo, Cecilia Carpio, Mónica Bolufer , et al. · 2024

Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy.

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies Open

Juan León-Román, Gloria Iacoboni, Sheila Bermejo, Cecilia Carpio, Mónica Bolufer , et al. · 2024

Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cel…

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy Open

Edwin Wong, Carla Nester, Teresa Cavero, Alexandre Karras, Moglie Le Quintrec , et al. · 2023

Iptacopan resulted in statistically significant and clinically important reductions in UPCR and normalization of serum C3 levels in the native cohort and reduced C3 deposit scores in the recurrent KT cohort with favorable safety and tolera…

Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology Open

Fabiola Alonso, Ángel L.M. Martín de Francisco, Pilar Auñón, Clara García-Carro, Patricia García , et al. · 2023

The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point…

Genetic testing in focal segmental glomerulosclerosis: in whom and when? Open

A Tato, Noa Carrera, María García-Murias, Amir Shabaka, Ana Ávila , et al. · 2023

Background Genetic causes are increasingly recognized in patients with focal segmental glomerulosclerosis (FSGS), but it remains unclear which patients should undergo genetic study. Our objective was to determine the frequency and distribu…

Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN) Open

Jorge Rojas-Rivera, Clara García-Carro, Ana I Ávila, M. Espino Hernández, Mario Espinosa , et al. · 2023

Lupus nephritis (LN) is the most frequent serious manifestation of patients with systemic lupus erythematosus (SLE). Up to 60% of SLE patients develop LN, which has a significant impact on their quality of life and prognosis. Recent advanc…

Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival Open

Clara García-Carro, Kenar D. Jhaveri, Ben Sprangers · 2023

In the last decade, immune checkpoint inhibitors (ICI) have become a cornerstone in the treatment of a wide range of malignancies. It is well established that ICI are associated with multiple immune-related adverse events, a spectrum of au…

Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice Open

Marina Lopez-Martinez, Irina Torres, Sheila Bermejo, Francesc Moreso, Clara García-Carro , et al. · 2023

[This corrects the article DOI: 10.3389/ti.2022.10693.].

Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis Open

Jorge Rojas-Rivera, Clara García-Carro, Ana I Ávila, M. Espino Hernández, Mario Espinosa , et al. · 2023

A significant number of patients with systemic lupus erythematosus (between 20% and 60% according to different reported series) develop lupus nephritis in the course of its evolution, which directly influences their quality of life and vit…

Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica Open

Jorge Rojas-Rivera, Clara García-Carro, Ana I Ávila, M. Espino Hernández, Marío de la Torre Espinosa , et al. · 2022

Resumen: Un número importante de pacientes con lupus eritematoso sistémico (entre 20 a 60%, según diferentes series) desarrolla nefritis lúpica en el curso de su evolución, lo que influye directamente en su calidad de vida y pronóstico vit…

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice Open

Marina Lopez-Martinez, Irina B. Torres, Sheila Bermejo, Francesc Moreso, Clara García-Carro , et al. · 2022

Over 30% of patients with immunoglobulin A Nephropathy (IgAN) progress to end stage Chronic Kidney Disease and once they are transplanted, up to 50% suffer IgAN recurrence. Based on the gut-kidney axis, targeted-release-formulation budeson…

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI Open

Shruti Gupta, Clara García-Carro, Jason Prosek, Ilya Glezerman, Sandra M. Herrmann , et al. · 2022

Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause nu…

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity Open

Clara García-Carro, Juliana Draibe, María José Soler · 2022

The relation that connects cancer and renal damage is bidirectional and this renal damage worsens quality of life and increases morbidity in high-complexity patients such as patients with cancer and kidney injury. Strikingly, in the last d…

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study Open

Mónica Bolufer, Clara García-Carro, Miquel Blasco, Luís F. Quintana, Amir Shabaka , et al. · 2022

Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histologica…

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease? Open

Juan León-Román, Irene Agraz, Ander Vergara, Natàlia Ramos, Néstor Toapanta , et al. · 2022

Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AK…

Safety of Obtaining an Extra Biobank Kidney Biopsy Core Open

Sheila Bermejo, Clara García-Carro, Richard Mast, Ander Vergara, Irene Agraz , et al. · 2022

Background and objectives: Kidney biopsy (KB) is the “gold standard” for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with p…

COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry Open

Meryl Waldman, María José Soler, Clara García-Carro, Liz Lightstone, Tabitha Turner‐Stokes , et al. · 2021

Key Points Mortality and incidence of AKI do not differ between coronavirus disease 2019 (COVID-19) patients with or without glomerular diseases. The main predictor of AKI is pre-COVID-19 eGFR, independent of the presence of GN. Incomplete…

Focal and segmental glomerulosclerosis associated with COVID-19 infection Open

Juan León Román, Ander Vergara, Irene Agraz, Clara García-Carro, Sheila Bermejo , et al. · 2021

Acute kidney injury in patients treated with immune checkpoint inhibitors Open

Shruti Gupta, Samuel Short, Meghan E. Sise, Jason Prosek, Sethu M. Madhavan , et al. · 2021

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received…

SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP Open

José M Zuniga, David Toapanta, Natàlia Ramos, Sònia Caparrós, Juan León-Román , et al. · 2021

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR Open

Clara García-Carro, Ander Vergara, Sheila Bermejo, María Azancot, Ana Sánchez‐Fructuoso , et al. · 2021

Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made a…

Clara García-Carro YOU? Author Swipe